The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker expects 2024 to turn out largely better than expected too, as new products build momentum. Lilly debuted on Tuesday a forecast for the new year that calls for adjusted earnings ranging from $12.20 to $12.70 per share as its new weight-loss … Read more
Advances in Diabetes Treatment By Camille PeriWebMD Feature WebMD Feature Archive Diabetes treatment is getting better every day. Scientists may be just a few years away from making an artificial pancreas that can safely detect and adjust blood sugar (glucose) levels. In the meantime, new medications and insulin devices can make living with … Read more
STAVANGER — Norway’s oil fund reported the largest annual return in its history Tuesday, a performance led by U.S. technology companies and Danish pharmaceutical company Novo Nordisk, which makes the diabetes-turned-weight loss drug Ozempic. Norway’s Government Pension Fund Global, the world’s largest sovereign wealth fund, said it also benefited in 2023 from market excitement over … Read more
This article is part of HuffPost’s biweekly politics newsletter. Click here to subscribe. Lots of Americans say they are prepared to vote against President Joe Biden in November. Among the many reasons seems to be a persistent belief that Biden has accomplished “not very much” or “little or nothing” (according to an ABC-Washington Post poll … Read more
PHOENIX — With his gap-tooth smile, hip-hop routines and volunteer work for a food charity, Roosevelt White III was well known in the downtown Phoenix tent city known as “The Zone.” But like many homeless people, White suffered from diabetes and cardiovascular disease. He died unexpectedly one sweltering September day at age 36. Thousands of … Read more
Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost significant weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A … Read more
